Blood tests to predict how well ovarian cancer maintenance treatment works

Plain-English translation of NCT05027828 on ClinicalTrials.gov ↗ · Source last updated April 2026 · Translation generated June 2026 · How we translate trials

What is this trial?

Researchers are testing whether a blood test that detects circulating tumor DNA (fragments of cancer cells in your bloodstream) can predict how well olaparib — a type of maintenance therapy — works for your ovarian cancer. This is an observational study, meaning doctors will monitor your blood samples and medical information over time to see if this blood test can reliably tell them whether the medication is working and whether cancer might return.

Currently, doctors don't have an easy way to know early on whether maintenance treatment is working well for each individual patient or to catch cancer coming back before it shows up on scans. This blood test could help doctors personalize your care and catch recurrence much sooner.

Do you qualify?

You likely qualify if…

you have been newly diagnosed with high-grade serous epithelial ovarian cancer (or fallopian tube or peritoneal cancer)
your cancer is stage II, III, or IV
you are at least 18 years old
you will be having surgery as part of your treatment
you plan to receive maintenance therapy with olaparib (with or without bevacizumab) after chemotherapy
you fully understand the study and are willing to sign the consent form

You likely don't qualify if…

you have been diagnosed with a non-epithelial type of ovarian cancer
surgery cannot be performed as part of your treatment plan
you have been diagnosed with a different cancer within the past five years
you are unwilling or unable to take the standard maintenance medications being studied
you have severe heart disease, severe infection, or other serious medical conditions that cannot be controlled

What participation looks like

You will have blood samples taken at several points: before your surgery, after you finish chemotherapy, during your maintenance treatment, and if your cancer returns. You'll also share relevant medical information with the research team. The study lasts throughout your treatment period and any follow-up, so the exact timeline depends on your individual care plan.

AI-generated summary from trial data · Jun 9, 2026 · Not medical advice

Trial locations(1 site)

China

Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai